Guardion Health Sciences Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים GHSI

An innovative approach to developing ophthalmological nutraceuticals strengthens the fundamental profile of Guardion Health Science (GHSI). The annual shift in EPS TTM demonstrates pricing power, while 77.10 captures the magnitude of this parameter. Financial reserves are supported by the robotization of packaging and a compact staff of loyal scientists, despite a shortage of expensive top managers. This twelve-month profit trend clearly illustrates the business development vector.

Given the complete liquidation of the Guardion Health Science operational business, the 12-month YoY EPS growth chart reflects the distribution of residual assets rather than growth. This metric compares current annual earnings with the same period, highlighting discrepancies between GAAP and Non-GAAP standards. Variance analysis allows for the separation of one-time accounting adjustments from actual cash flow. The trade-off formula here correlates adjusted income with the risks associated with the final closure of the structure. Current price action confirms a lack of fundamental stability in favor of the cessation of operations.